RxDoctor Payments Data

Payal Soni-Patel, PA

Medical · Asheville, NCNPI 1093793192

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $59,079 of the $75,976 with a category attached, or 77.8%. AbbVie accounts for 82.4% of it on its own, with 59 other manufacturers making up the rest. Reporting peaked in 2021 at $30,491 and has fallen 77.7% since, to $6,784 in 2025. Among medical clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$75,976in general payments, 2019–2025

Across 833 payments — averaging $91.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$63K
  • MDD US Operations, LLC$880
  • UCB, Inc.$795
  • Teva Pharmaceuticals USA, Inc.$593
  • AstraZeneca$555
  • TG Therapeutics, Inc.$435
  • plus $10K from 54 others

What the payments were for

  • Speaking & faculty fees$59,07978%
  • Travel & lodging$1,1632%
  • Food & beverage$15,68121%
  • Education$530%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)284$62,617
MDD US Operations, LLC10$880
UCB, Inc.28$795
Teva Pharmaceuticals USA, Inc.30$593
AstraZeneca(2 entities)25$555
TG Therapeutics, Inc.10$435
Lundbeck LLC16$411
Acadia Pharmaceuticals Inc17$403
Biogen24$394
Eisai Inc.13$373
Bristol Myers Squibb19$370
Argenx US, Inc.11$351
Sanofi10$349
Averitas Pharma Inc.20$347
Lilly USA, LLC15$344
Neurocrine Biosciences, Inc.14$343
Novartis22$327
SK Life Science, Inc.13$312
Biohaven Pharmaceuticals, Inc.9$271
Livanova USA, Inc.4$269
Neurelis, Inc.8$265
Jazz Pharmaceuticals Inc.11$253
Amgen(2 entities)10$238
Catalyst Pharmaceuticals, Inc.10$218
Amneal Pharmaceuticals LLC11$213
EMD Serono, Inc.10$213
Pfizer11$208
Ipsen Biopharmaceuticals, Inc9$206
Merz Pharmaceuticals, LLC8$189
Johnson & Johnson(2 entities)8$171
E.r. Squibb & Sons, L.L.C.4$158
Avanir Pharmaceuticals, Inc.7$130
Acorda Therapeutics, Inc6$129
Alnylam Pharmaceuticals Inc.5$128
Supernus Pharmaceuticals, Inc.6$123
Mallinckrodt Hospital Products Inc.4$120
Sunovion Pharmaceuticals Inc.9$118
Sumitomo Pharma America, Inc.7$114
Tanabe Pharma America, Inc.5$114
Otsuka Pharmaceutical Development & Commercialization, Inc.1$112
CSL Behring4$102
Upsher-smith Laboratories LLC4$90
Takeda Pharmaceuticals U.S.A., Inc.3$86
Genentech USA, Inc.4$84
Ultragenyx Pharmaceutical Inc.3$76
Biohaven Pharmaceutical Holding Company Ltd.4$74
Insightec,inc3$73
Kyowa Kirin, Inc.4$72
GRT US Holding, Inc.8$69
Greenwich Biosciences, Inc.4$68
Scilex Pharmaceuticals Inc.3$67
Otsuka America Pharmaceutical, Inc.3$66
Xeris Pharmaceuticals, Inc.2$65
Abbott4$62
Vanda Pharmaceuticals Inc.3$62
Axonics, Inc.1$56
ANI Pharmaceuticals, Inc.4$54
Axsome Therapeutics, Inc.2$50
Novo Nordisk1$50
Banner Life Sciences, LLC2$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$75,976 in reported general payments places this provider in the 95th percentile of 878 medical providers in North Carolina.

See all medical providers in North Carolina

Medicare billing

Part B allowed, 2024
$18,731
Medicare patients
138
Services billed
246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate11$81,252
QutenzaCapsaicin/Skin Cleanser22$77,150
UbrelvyUbrogepant31$46,113
Emgality PenGalcanezumab-Gnlm60$42,744
Aimovig AutoinjectorErenumab-Aooe50$41,516
QuliptaAtogepant25$39,247
Dimethyl Fumarate17$28,478
RytaryCarbidopa/Levodopa16$27,825
LamictalLamotrigine14$27,199
Nurtec OdtRimegepant Sulfate20$24,372
Lacosamide99$12,460
Dalfampridine ErDalfampridine18$10,091
LinzessLinaclotide16$9,874
Ajovy SyringeFremanezumab-Vfrm13$9,052
Carbidopa-LevodopaCarbidopa/Levodopa324$8,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Linzess$62,617$95,23472 claims
Neurocrine Biosciences, Inc.Ingrezza$343$81,25211 claims
GRT US Holding, Inc.Qutenza$69$77,15022 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$213$29,92840 claims
PfizerNurtec Odt$208$24,37220 claims
Upsher-smith Laboratories LLCTopiramate$90$1,510120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 878 medical providers in North Carolina.

Other medical in Asheville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →